Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Antiviral deal coming?

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Oct 08, 2024 10:09pm

271 Views

Post# 36258784

RE:RE:RE:RE:Antiviral deal coming?

Johnandrose22 wrote: CancerSlayer...thank you...Could you envision the use of Rutherin to leap frog past all of the current intravesical limitations for MIBC and beyond? In short, I wonder whether Rutherin would even make Ruvidar (and its corresponding enhancements) obsolete over time.

That being said...Ruvidar is extraordinary!

I hesitate giving any kind of non-expert predictions, however, from a technical standpoint, I can see potential for a two-front approach via use of a combination of a systemic (i.e. Rutherrin) & an intravesical therapy for MIBC that has coexisting CIS, which may ultimately also require a partial cystectomy.

So if all goes well with this trial, I think Ruvidar would continue to have an important role for more accessible/superficial tumors that systemic therapies cannot adequately reach. However, I think Rutherrin will be the star of this drug-drug partnership as it opens up so many treatment possibilities throughout the body for potentially any stage of cancer (local, distant progression, advanced & metastatic). JMHO.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?